Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEN2312 + elacestrant
- Development stage
- Unknown
- Lead developer
- Menarini
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MEN2312 + elacestrant is a combination regimen under investigation for advanced breast cancer. **MEN2312** is a small molecule inhibitor targeting lysine acetyltransferase 6 (KAT6), an epigenetic regulator implicated in cancer cell proliferation and survival. **Elacestrant** is an oral estrogen receptor antagonist (SERD, selective estrogen receptor degrader) that binds and degrades estrogen receptor-alpha (ERα), inhibiting estrogen-driven tumor growth. The combination is designed to address resistance mechanisms in hormone receptor-positive, HER2-negative advanced breast cancer, especially after progression on prior endocrine therapies and CDK4/6 inhibitors. This combination is being tested in clinical trials for efficacy and safety[5][2][3][6].
- Other names
- MEN2312 + elacestrantOrserdu + MEN2312elacestrant dihydrochloride + MEN2312
02
Targets
KAT6A (Lysine acetyltransferase 6A)ESR1 (ERα)KAT6B (Histone acetyltransferase KAT6B)
Beyond the preview
Go deeper on MEN2312 + elacestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEN2312 + elacestrant.